HBOT Effects on First Responders' Cognition and Well-Being

September 25, 2026 updated by: Steve Wyman, Summit Hyperbarics and Wellness

Changes in Cognitive Functioning, Psychological Well-Being, and Quality of Life Following Hyperbaric Oxygen Therapy in First Responders

The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are:

  1. Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions?
  2. Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment?

Approximately 54 participants will:

  • Complete medical and behavioral health screening.
  • Complete cognitive tests and questionnaires before and after treatment.
  • Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions.

All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This prospective, single-arm study will examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in approximately 54 current or former first responders with a history of traumatic brain injury (TBI). Secondary outcomes include symptoms of post-traumatic stress disorder (PTSD), depression, and anxiety, as well as quality of life.

After providing informed consent, participants will undergo medical and behavioral health screening to determine eligibility for HBOT. Eligible participants will complete baseline cognitive testing and questionnaires measuring post-concussive symptoms, psychological symptoms, and quality of life. These assessments will be repeated after treatment.

Participants will receive 40 HBOT sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). Each session will include two 30-minute periods of breathing 100% oxygen separated by a 5-minute air break. Sessions will take place twice daily, Monday through Friday, with at least four hours between sessions. A physician will prescribe and oversee treatment, and trained hyperbaric personnel will operate the chamber and monitor participants.

Changes between baseline and post-treatment assessments will be analyzed within participants. The study will also explore whether demographic or clinical characteristics are associated with the magnitude of change. All participants will receive HBOT; there is no randomized or untreated comparison group. As a result, the study can describe changes observed following treatment but cannot establish that HBOT caused those changes.

Study Type

Interventional

Enrollment (Estimated)

54

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Idaho
      • Boise, Idaho, United States, 83716
        • Recruiting
        • Summit Hyperbarics and Wellness
        • Contact:
        • Principal Investigator:
          • Steve Wyman, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  1. Adults aged 18 to 75 years.
  2. Current or former first responder.
  3. Clinically diagnosed with a traumatic brain injury (TBI) and current or persistent post-concussive syndrome, as determined by a qualified health care professional.
  4. Participants with comorbid PTSD, depression, or anxiety may be enrolled if all other eligibility criteria are met; these symptoms will be assessed as secondary/exploratory outcomes.
  5. Ability to provide informed consent, including the ability to read, understand, and voluntarily sign the informed consent document.
  6. Completion of baseline cognitive and psychological assessment measures as part of study enrollment procedures.
  7. Presence of clinically significant symptoms resulting in functional impairment in occupational, social, or other key areas of functioning, as determined by clinical evaluation.
  8. Sexually active female participants of childbearing potential and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of contraception for the duration of the study and for 30 days following the final HBOT session.
  9. Stable regimen of psychoactive medications (if applicable), including antidepressants, anxiolytics, antipsychotics, stimulants, and mood stabilizers, for a clinically appropriate stabilization period prior to enrollment, as determined by the study physician.

Exclusion criteria

  1. Untreated pneumothorax
  2. History of spontaneous pneumothorax
  3. Severe sinus infection
  4. Upper respiratory infection
  5. Asymptomatic pulmonary lesions on chest x-ray
  6. Uncontrollable high fever (greater than 39C)
  7. History of chest or ear surgery
  8. Congenital spherocytosis
  9. Any anemia or blood disorder
  10. Any convulsive disorder
  11. History of optic neuritis or sudden blindness
  12. Middle ear infection
  13. Diabetes mellitus (insulin therapy)
  14. The participant is pregnant or lactating
  15. Nicotine use/substance use/addiction
  16. Acute Hypoglycemia
  17. Diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Emphysema
  18. Presenting with symptoms of cough, congestion, vomiting, diarrhea, or open wounds.
  19. Active malignancy
  20. Current manic, delusional, or psychotic episodes
  21. Serious/current suicidal ideations
  22. Severe or unstable physical disorders or major cognitive deficits
  23. Inability to attend scheduled clinic visits or comply with study protocols.
  24. Treated with HBOT for any reason prior to study enrollment.
  25. Non-English speakers
  26. History of retinal repair, including laser photocoagulation or retinal detachment surgery.
  27. History of middle ear surgery, including tympanoplasty, mastoidectomy, or pressure equalization tube placement.
  28. Age greater than 75 years.
  29. Use of any of the following medications during the study period: Anti-metabolites (e.g., methotrexate, azathioprine); Chemotherapuetic agents (e.g., cyclophosphamide, cisplatin); Mafenide acetate e.g., Sulfamylon); Disulfiram (e.g, Antabuse); Peripheral vasodilators known to interact with oxygen exposure (e.g., nitroglycerin); and Antibacterial drugs with known HBOT interaction risks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hyperbaric Oxygen Therapy

Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment.

Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in NeuroTrax Global Cognitive Score
Time Frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in Global Cognitive Score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score
Time Frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in post-concussive symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in PTSD Checklist for DSM-5 (PCL-5) score
Time Frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in PTSD symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in Patient Health Questionnaire-9 (PHQ-9) score
Time Frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in depression symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in Generalized Anxiety Disorder-7 (GAD-7) score
Time Frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in anxiety symptom score from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in World Health Organization Quality of Life-BREF (WHOQOL-BREF) domain scores
Time Frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Change in quality-of-life scores from baseline to completion of 40 HBOT sessions.

Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Steve Wyman, MD, Summit Hyperbarics and Wellness

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 11, 2026

Primary Completion (Estimated)

September 11, 2027

Study Completion (Estimated)

September 11, 2027

Study Registration Dates

First Submitted

September 25, 2026

First Submitted That Met QC Criteria

September 25, 2026

First Posted (Actual)

October 1, 2026

Study Record Updates

Last Update Posted (Actual)

October 1, 2026

Last Update Submitted That Met QC Criteria

September 25, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no current plan to share IPD outside the study team. Given the relatively small sample of first responders and the sensitive clinical and occupational information collected, sharing participant-level data could increase the risk of re-identification. Study findings will be reported in aggregate.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.